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a  b  s  t  r  a  c  t
The  genetic  predispositions  which  describe  a diagnosis  of  familial  Alzheimer’s  disease  can  be considered
as  cornerstones  of  the  amyloid  cascade  hypothesis.  Essentially  they  place  the  expression  and metabolism
of  the  amyloid  precursor  protein  as  the main  tenet  of  disease  aetiology.  However,  we  do  not  know  the
cause  of  Alzheimer’s  disease  and  environmental  factors  may  yet  be shown  to contribute  towards  its
onset  and  progression.  One  such  environmental  factor  is human  exposure  to aluminium  and  aluminium
has  been  shown  to be present  in brain  tissue  in sporadic  Alzheimer’s  disease.  We  have  made  the ﬁrst
ever  measurements  of  aluminium  in  brain  tissue  from  12  donors  diagnosed  with  familial  Alzheimer’s
disease.  The  concentrations  of aluminium  were extremely  high,  for example,  there  were  values  in excess
of 10  g/g tissue  dry  wt. in 5 of the 12 individuals.  Overall,  the  concentrations  were  higher  than  all
previous  measurements  of  brain  aluminium  except  cases  of known  aluminium-induced  encephalopathy.
We  have  supported  our  quantitative  analyses  using  a  novel  method  of  aluminium-selective  ﬂuorescence
microscopy  to visualise  aluminium  in all lobes  of  every  brain  investigated.  The  unique  quantitative  data
and  the  stunning  images  of  aluminium  in  familial  Alzheimer’s  disease  brain  tissue raise  the  spectre  of
aluminium’s  role  in  this  devastating  disease.
©  2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Genetic mutations associated with both the expression [1] and
metabolism [2] of amyloid precursor protein (APP) are, in general,
the basis for a diagnosis of familial Alzheimer’s disease (fAD). They,
along with evidence from Down’s syndrome [3], provide strong
support for the amyloid cascade hypothesis [4,5] and a central role
for the neuropathology and biochemistry of amyloid-beta (A)  in
Alzheimer’s disease [6]. In many ways, familial AD has been used
as a blueprint for understanding and treatment of sporadic or late-
onset AD.
Aluminium is present in human brain tissue [7] and in a recent
study involving 60 human brains the median aluminium content
of 712 tissues across all four main lobes was 1.02 g/g dry wt.  with
75% of all values being <2.01 g/g dry wt. tissue [8]. The associa-
tion of aluminium and AD has a signiﬁcant history [9,10] and yet
there remains no consensus as to a role for this known neurotoxin
in the disease [11]. However, recent reports concerning sporadic
AD [12] and environmental [13] and occupational [14] exposure to
∗ Corresponding author.
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aluminium have allowed the conclusion to be drawn that, under
certain conditions, it is inevitable that aluminium will contribute
towards AD [11,15]. The suggestion is made that wherever in the
brain the concentration of aluminium is pathologically-concerning
(>2.00 g/g dry wt.) that this aluminium will contribute towards
any ongoing AD and will result in the disease being earlier in onset
with a more aggressive aetiology [15].
Familial AD is characterised by an earlier age of onset and yet
there are no data to describe the aluminium content of brain tissue
in this ‘signature’ form of AD. Herein we have obtained brain tissue
from 12 autopsy-conﬁrmed cases of familial AD and we have car-
ried out the ﬁrst ever measurements of brain aluminium content
in familial AD. We have also supported our quantitative measure-
ments with imaging of brain aluminium by aluminium-selective
ﬂuorescence microscopy.
2. Materials and methods
There was  ethical approval from The MRC London Neu-
rodegenerative Diseases Brain Bank at King’s College, London
(08/MRE09/38 + 5).
Samples of cortex of approximately 1 g frozen weight from tem-
poral, frontal, parietal and occipital lobes were obtained from 12
http://dx.doi.org/10.1016/j.jtemb.2016.12.001
0946-672X/© 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Fig. 1. Representative images of aluminium in frontal cortex. Light (A&D) and ﬂuorescence (B&E) microscopy images of lumogallion-stained sections of frontal cortex. Asterisk
label  suggested intracellular deposits while arrows show diffuse deposits. Fluorescence microscopy of un-stained adjacent tissue sections (C&F) show autoﬂuorescence. Scale
bars  are all 100 m.
Fig. 2. Representative images of aluminium in parietal cortex. Light (A&D) and ﬂuorescence (B&E) microscopy images of lumogallion-stained sections of frontal cortex. Asterisk
label  suggested intracellular deposits associated with both living and dead cells. Fluorescence microscopy of un-stained adjacent tissue sections (C&F) show autoﬂuorescence.
Scale  bars are 100 m (A–C) and 50 m (D–F).
cases of autopsy-conﬁrmed familial Alzheimer’s disease. Donors
with familial Alzheimer’s disease are extremely rare and we had
the privilege of obtaining tissue from the only 12 cases available
at the brain bank with the year of diagnosis ranging from 1991
through to 2009. There were 7 female and 5 male donors in the age
range 42–86. The bases for a diagnosis of familial Alzheimer’s dis-
ease are given in Table 1. Where no deﬁnite genetic mutation was
recorded at the time of autopsy we have deﬁned probable famil-
ial Alzheimer’s disease as either (i) having two ﬁrst degree relatives
with a dementing illness or (ii) where the patient or ﬁrst degree rel-
ative had developed symptoms of dementia at less than 60 years of
age or (iii) where the patient had one ﬁrst and one second degree
relative with dementia and one with symptoms of dementia at less
than 60 years of age.
The aluminium content of these tissues was  measured by
an established and fully validated method [8] which herein is
described brieﬂy. Thawed tissues were cut using a stainless steel
blade to give individual samples of ca 0.3 g (3 sample replicates
for each lobe) wet weight and dried to a constant weight at 37 ◦C.
Dried and weighed tissues were digested in a microwave (MARS
Xpress CEM Microwave Technology Ltd.) in a mixture of 1 mL
15.8 M HNO3 (Fisher Analytical Grade) and 1 mL 30% w/v H2O2 (BDH
Aristar). Digests were clear with no fatty residues and, upon cool-
ing, were made up to 5 mL  volume using ultrapure water (cond
<0.067 S/cm). Total aluminium was measured in each sample
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Fig. 3. Representative images of aluminium in cortex. Light (A&D) and ﬂuorescence (B&E) microscopy images of lumogallion-stained sections of frontal (A&B) and temporal
(D&E)  cortex. Asterisk label suggested intracellular deposits and arrows diffuse deposits. Fluorescence microscopy of un-stained adjacent frontal (C) and temporal (F) tissue
sections  show autoﬂuorescence. Scale bars are 50 m (A–C) and 100 m (D–F).
Fig. 4. Co-localisation of amyloid and aluminium in occipital cortex. (A) Light microscopy image of Congo red-stained tissue showing (arrow) senile plaque-like amyloid
deposit. (B) Polarising microscopy image of Congo red-stained image showing (arrow) apple-green birefringence characteristic of amyloid in  sheet conformation. (C)
Fluorescence microscopy image of Congo red-stained tissue showing (arrow) senile plaque-like amyloid deposit. (D) Fluorescence microscopy image of adjacent section of
tissue  stained with lumogallion and showing (arrow) signiﬁcant deposits of aluminium. Scale bars are all 50 m.
by transversely-heated graphite furnace atomic absorption spec-
trometry (TH GFAAS) using matrix-matched standards and an
established analytical programme [8].
Formalin-ﬁxed brain tissue for 6 cases of familial AD (A1, A5,
A7, A8, A11 & A12) was supplied as pre-embedded parafﬁn blocks
representing cortical tissue from frontal, parietal, and temporal
and occipital lobes. A recently developed, optimised and validated
method using lumogallion and ﬂuorescence microscopy was  used
to identify the presence of aluminium in tissues [16]. This method
was shown to be speciﬁc for aluminium with no interference
from any other metals and no issues relating to autoﬂuorescence.
Slides of serial adjacent sections of tissue were imaged using an
Olympus BX50 ﬂuorescence microscope with a BX-FLA reﬂected
light ﬂuorescence attachment, equipped with a mercury burner
and a vertical illuminator. For lumogallion (and autoﬂuorescence)
imaging a U-MNIB3 ﬂuorescence ﬁlter cube was used (bandpass
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excitation ﬁlter: 470–495 nm,  dichromatic mirror: 505 nm,  long-
pass emission ﬁlter: 510 nm)  (both from Olympus, UK). Images
were obtained using CellD software (Olympus Soft Imaging Solu-
tions GmbH).
3. Results
3.1. Aluminium content of brain tissues
Aluminium was found in all 144 tissues and its concentration
ranged from 0.01 to 35.65 g/g dry wt. (Table 1). The mean alu-
minium content for whole brains (n = 12) ranged from 0.34(0.26)
for individual A1 to 6.55(9.59) g/g dry wt. for individual A8.
Approximately 40% of tissues (57/144) had an aluminium con-
tent considered as pathologically-concerning (≥2.00 g/g dry wt.)
while approximately 58% of these tissues had an aluminium con-
tent considered as pathologically-signiﬁcant (≥3.00 g/g dry wt.).
The brains of 11 out of 12 individuals had at least one tissue with
a pathologically-signiﬁcant content of aluminium. The brains of
9 individuals had at least one tissue with an aluminium content
≥5.00 g/g dry wt. while 5 of these had at least one tissue with an
aluminium content ≥10.00 g/g dry wt.  (Table 1). The mean (SD)
Table 1
The content of aluminium in each of 4 lobes (O – occipital; F – frontal; T – temporal; P – parietal) of 12 cases of familial Alzheimer’s disease. Values considered as pathologically-
concerning or pathologically-signiﬁcant are given in italics or bold typescript respectively. Details of pathology and known genetic mutations are also given. PSEN – presenilin,
APP  – amyloid precursor protein, BNE – Brain Net Europe.
Donor  ID  Pathology  and  genetics  Gender  Age  Lobe  Replicate  [Al]  g/g  dry  wt.
A1  Braak/BNE  stage  VI  M  47 O 1 0.47
2 0.67
3 0.03
Grandfather, father,  brother  died  F  1 0.84
with dementia,brother  had  a  2 0.52
PSEN-1 mutation 3  0.13
T 1 0.16
2 0.02
3 0.29
P 1 0.53
2 0.28
3 0.13
Mean(SD)  0.34(0.26)
A2 Braak  Stage  VI  F 76 O 1 10.12
2 8.32
Father and  nephew  died  with  3 11.54
dementia, nephew  developed  F  1 1.75
dementia at  young  age  2 4.48
3 0.48
T 1 0.69
2 0.55
3 0.16
P 1 0.27
2 1.25
3 1.60
Mean(SD)  3.43(4.17)
A3 Braak  Stage  V-VI  M  53 O 1 2.07
2 2.83
Father died  at  young  age  with  3 7.97
AD F  1 3.23
2 1.55
3 3.93
T 1 0.70
2 1.41
3 2.72
P 1 3.18
2 2.17
3 5.32
Mean(SD)  3.09(1.97)
A4 Braak  Stage  V-VI  M  42 O 1 0.10
2 4.79
PSEN-1(DELTA4) 3 0.52
F 1 3.11
2 0.85
3 1.48
T 1 0.48
2 2.37
3 2.51
P 1 8.40
2 1.11
3 0.39
Mean(SD)  2.18(2.39)
A5 Braak  Stage  at  least  IV  M  60  O 1 0.59
2 0.73
Mother and  brother  died  in  their  3 0.14
50 s  with  dementia  F  1 1.24
2 6.51
3 13.41
T 1 0.77
2 0.34
3 0.25
P 1 2.61
2 0.41
3 0.54
Mean(SD)  2.30(3.93)
A6 Braak  stage  V-VI  F 86 O 1 25.80
2 0.66
Daughter died  in 30  s  with 3  2.25
dementia F  1 3.91
2 9.89
3 1.61
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Table 1 (Continued)
Donor  ID  Pathology  and  genetics  Gender  Age  Lobe  Replicate  [Al]  g/g  dry  wt.
T 1  0.24
2 2.54
3 1.05
P 1  0.89
2 1.87
3 1.23
Mean(SD)  4.33(7.23)
A7 Braak/BNE  stage  VI,cotton  wool  F 69  O 1  1.22
plaques (PSEN  mutation)  and 2  1.62
limbic Lewy  bodies  3  0.97
dementia diagnosed  at  age  46  F 1  1.08
2 1.11
3 3.00
T 1  2.69
2 1.19
3 1.56
P 1  0.54
2 0.01
3 0.32
Mean(SD)  1.28(0.87)
A8 Braak  stage  VI  with  Lewy  bodies  F 65  O 1  2.44
2 1.73
PSEN-1 (E280G)  3  2.12
F 1  5.06
2 2.53
3 35.65
T 1  10.43
2 6.31
3 6.77
P 1  3.82
2 0.36
3 1.38
Mean(SD)  6.55(9.59)
A9 Braak  Stage  V–VI,  Lewy  bodies  F 72  O 1  2.53
2 2.93
APP717(VAL-ILE) 3  0.81
F 1  8.56
2 1.28
3 1.46
T 1  2.48
2 0.65
3 2.61
P 1  1.36
2 5.44
3 0.96
Mean(SD)  2.59(2.30)
A10 Braak  Stage  VI,  Lewy  bodies  F 49  O 1  2.38
2 4.14
PSEN-1 (L153V)  3  2.40
F 1  2.60
2 0.63
3 1.26
T 1  2.37
2 0.12
3 1.99
P 1  1.14
2 0.76
3 0.28
Mean(SD)  1.67(1.18)
A11 Braak  Stage  V-VI  F 69  O 1  23.93
2 0.85
APP717(VAL-ILE) 3  3.15
F 1  1.45
2 0.84
3 1.02
T 1  1.41
2 0.41
3 6.21
P 1  0.55
2 2.27
3 0.37
Mean(SD)  3.54  (6.63)
A12 Braak  at  least  Stage  IV  M  61  O 1  4.57
2 1.93
APP717(VAL-GLY) 3  0.85
F 1  1.81
2 2.54
3 0.84
T 1  6.00
2 0.27
3 2.47
P 1  5.41
2 0.66
3 0.01
Mean(SD)  2.28(2.03)
aluminium content across all 12 individuals for each lobe were
3.89(5.86), 3.66(6.18), 2.03(2.35) and 1.61(1.90) g/g dry wt.  for
the occipital, frontal, temporal and parietal lobes respectively. The
aluminium content of the parietal lobe was statistically different
to the occipital lobe (P = 0.029; df = 70) but there were no other
statistically signiﬁcant differences in lobe aluminium content.
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3.2. Aluminium ﬂuorescence in brain tissues
Tissue sections from 6 of the 12 familial AD cases (A1, A5, A7,
A8, A11 & A12) were investigated and the presence of aluminium
was conﬁrmed in each case using lumogallion and ﬂuorescence
microscopy. Representative images of positive aluminium ﬂuo-
rescence are shown in Figs. 1–3. Multiple deposits of aluminium
were identiﬁed in each case and including in the brain of donor
A1 which had the lowest mean aluminium content by TH GFAAS.
Aluminium was primarily identiﬁed in grey matter as clusters or
swathes of focal deposits some of which were densely stained and
1–5 m in size while others were diffuse and up to 50 m in length
or diameter. Many of the former gave the impression of being
intracellular being associated with astrocytes or neurons or tissue
spaces vacated by dead or dying cells. The more diffuse deposits
appeared to be extracellular and were similar in appearance to dif-
fuse deposits of A. Aggregates of lipofuscin were common in most
tissues and some deposits of aluminium shared the appearance of
accumulations of lipofuscin.
4. Discussion
The aluminium content of brain tissue donated by individuals
with a diagnosis of familial and probable familial Alzheimer’s dis-
ease was, overall, extremely high. The mean aluminium data for
each lobe across all 12 donors are signiﬁcantly higher (P < 0.05 in
each case) than equivalent data (using identical methods and qual-
ity assurance indices) for the same lobes from a previous study
which included 60 human brains of which ca 60% had been diag-
nosed as sporadic Alzheimer’s disease [8,12]. Herein we measured
some of the highest values recorded for individual samples of
human brain tissue, for example to highlight just a few, 11.54 g/g
in the occipital lobe of donor A2, 13.41 g/g in the frontal lobe of
A5, 25.80 g/g in the occipital lobe of A6, 35.65 g/g in the frontal
lobe of A8 and 23.93 g/g in the occipital lobe of A11 (Table 1).
These individual values are higher than previous measurements
for non-AD and sporadic or late-onset AD brain tissue [7,8,12].
While we have previously recorded values up to ca 13.00 g/g in
AD with occupational exposure to aluminium [14] and one value
of 23.00 g/g in congophilic amyloid angiopathy (CAA) with envi-
ronmental exposure to aluminium [13] the values measured herein
for familial AD are more similar to those which have been associ-
ated with aluminium-induced encephalopathies [17]. It was of note
that while the aluminium content of brain tissue from donor A1
was consistently low across all 4 lobes (mean (SD) 0.34(0.26) g/g)
when additional tissues from this donor were investigated by
ﬂuorescence microscopy signiﬁcant deposits of aluminium were
identiﬁed across all 4 lobes. This observation tends to support the
previous contention of focal as opposed to homogeneous distribu-
tion of aluminium in human brain tissues [7,14].
The presence of aluminium in brain tissue from donors with
familial AD was fully supported qualitatively by aluminium-
speciﬁc ﬂuorescence microscopy (Figs. 1–3). We  have produced
striking and unequivocal images of aluminium in human brain tis-
sue and conﬁrmed aluminium’s presence in each of the familial AD
brains investigated. Aluminium appeared to be both intracellular,
associated with dead and dying neurones and extracellular in large
diffuse deposits. Further detailed research will be required to con-
ﬁrm the precise locations of deposits of aluminium. Our images may
support previous studies using various semi-quantitative tech-
niques which suggested the co-localisation of aluminium with;
neurones and neuroﬁbrillary tangles in AD [10] and dementia
pugilistica [18]; Lewy bodies in Parkinson’s disease [19]; lipofuscin
in AD [20] and senile plaques in AD [21]. We  have previously iden-
tiﬁed the co-localisation of aluminium and amyloid in an AD brain
[7] and we  have additional evidence herein to support this (Fig. 4).
Aluminium is shown in the very near vicinity of a plaque-like struc-
ture which stained positively with Congo red and gave apple-green
birefringence under polarised light. However, emission spectra for
Congo red and lumogallion show signiﬁcant overlap and so addi-
tional research will be required to provide unequivocal evidence
by ﬂuorescence microscopy for the association of aluminium with
amyloid in diseased human brain tissue.
These data, supported by visual evidence of aluminium in brain
tissue, raise the possibility that genetic predisposition to AD is
accompanied by a higher propensity to accumulate and retain alu-
minium in the brain. In familial AD the expression and metabolism
of APP is altered and there is substantial evidence of a role for
A in disease aetiology [6]. The observation that A binds alu-
minium promoting its precipitation in a -sheet conformation
[22,23] alongside the known co-localisation of aluminium and A
in human brain tissue [7] might suggest a role for A in the reten-
tion and accumulation of aluminium in brain tissue in familial AD.
5. Conclusions
Aluminium is neurotoxic [11,23] and the concentrations of alu-
minium found in these familial AD brains are unlikely to be benign
and indeed are highly likely to have contributed to both the onset
and the aggressive nature of any ongoing AD in these individu-
als. These data lend support to the recent conclusion that brain
aluminium will contribute towards all forms of AD under certain
conditions [15].
Competing interests
The authors declare that they have no competing interests.
Author contributions
AK and CT organised tissue donations, conﬁrmed diagnoses of
fAD and performed neuropathological examinations. AM and CE
measured Al content of tissue and AM performed all light and ﬂu-
orescence microscopy. CE wrote the manuscript. All authors read
and commented on the ﬁnal manuscript.
Acknowledgements
This research is supported by an Acorn (CMSRI/Keele University)
PhD studentship awarded to AM.  Dr MJ  Mold is thanked for his help
in developing the lumogallion staining method.
References
[1] A. Goate, M.C. Chartierharlin, M.  Mullan, J. Brown, F. Crawford, Segregation of
a  missense mutation in the amyloid precursor protein gene with familial
Alzheimer’s-disease, Nature 349 (1991) 704–706.
[2] R. Sherrington, E.I. Rogaev, Y. Liang, E.A. Rogaeva, G. Levesque, Cloning of a
gene bearing missense mutations in early-onset familial Alzheimer’s disease,
Nature 375 (1995) 754–760.
[3] F.K. Wiseman, T. Al-Janabi, J. Hardy, A. Karmiloff-Smith, D. Nizetic, A genetic
cause of Alzheimer’s disease: mechanistic insights from Down’s syndrome,
Nat. Rev. Neurosci. 16 (2015) 564–574.
[4] J.A. Hardy, G.A. Higgins, Alzheimer’s disease: the amyloid cascade hypothesis,
Science 256 (1992) 184–185.
[5] J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer’s disease: progress
and problems on the road to therapeutics, Science 297 (2002) 353–356.
[6] D.R. Thal, J. Walter, T.C. Saido, M.  Fändrich, Neuropathology and biochemistry
of A and its aggregates in Alzheimer’s disease, Acta Neuropathol. 129 (2015)
167–182.
[7] C. Exley, E.R. House, Aluminium in the human brain, Monatsh. Chem. 142
(2011) 357–363.
[8] E. House, M. Esiri, G. Forster, P.G. Ince, C. Exley, Aluminium, iron and copper in
human brain tissues donated to the medical research council’s cognitive
function and ageing study, Metallomics 4 (2012) 56–65.
36 A. Mirza et al. / Journal of Trace Elements in Medicine and Biology 40 (2017) 30–36
[9] D.R. Crapper, S.S. Krishnan, A.J. Dalton, Brain aluminium distribution in
Alzheimer’s disease and experimental neuroﬁbrillary degeneration, Science
180 (1973) 511–513.
[10] D.P. Perl, A.R. Brody, Alzheimer’s disease – x-ray spectrometric evidence of
aluminium accumulation in neuroﬁbrillary tangle-bearing neurons, Science
208 (1980) 297–299.
[11] C. Exley, What is the risk of aluminium as a neurotoxin? Expert Rev.
Neurother. 14 (2014) 589–591.
[12] C. Exley, E. House, A. Polwart, M.M.  Esiri, Brain burdens of aluminium, iron
and  copper and their relationships with amyloid- pathology in 60 human
brains, J. Alzheimers Dis. 31 (2012) 725–730.
[13] C. Exley, M.  Esiri, Severe cerebral congophilic angiopathy coincident with
increased brain aluminium in a resident of Camelford, Cornwall, UK, J. Neurol.
Neurosurg. Psychiatry 77 (2006) 877–879.
[14] C. Exley, T. Vickers, Elevated brain aluminium and early onset Alzheimer’s
disease in an individual occupationally exposed to aluminium: a case report,
J.  Med. Case Rep. 8 (2014) 41.
[15] C. Exley, Why  industry propaganda and political interference cannot disguise
the inevitable role played by human exposure to aluminium in
neurodegenerative diseases including Alzheimer’s disease, Front. Neurol. 5
(2014) 212.
[16] A. Mirza, A. King, C. Troakes, C. Exley, The identiﬁcation of aluminium in
human brain tissue using lumogallion and ﬂuorescence microscopy, J.
Alzheimers Dis. 54 (2016) 1333–1338.
[17] E. Reusche, U. Seydel, Dialysis-associated encephalopathy-light and
electron-microscopic morphology and topography with evidence of
aluminium by laser microprobe mass analysis, Acta Neuropathol. 86 (1993)
249–256.
[18] C. Bouras, P. Giannakopoulos, P.F. Good, A. Hsu, P.R. Hof, D.P. Perl, A laser
microprobe mass analysis of brain aluminium and iron in dementia
pugilistica: comparison with Alzheimer’s disease, Eur. Neurol. 38 (1997)
53–58.
[19] E.C. Hirsch, J.P. Brandel, P. Galle, F. Javoyagid, Y. Agid, Iron and aluminium
increase in the substantia-nigra of patients with Parkinson’s disease – an
x-ray-microanalysis, J. Neurochem. 56 (1991) 446–451.
[20] S. Tokutake, S. Oyanagi, Accumulation of aluminium and silicon in lipofuscin
granules, Gerontology 41 (1995) 131–142.
[21] S. Yumoto, S. Kakimi, A. Ohsaki, A. Ishikawa, Demonstration of aluminium in
amyloid ﬁbres in the cores of senile plaques in the brains of patients with
Alzheimer’s disease, J. Inorg. Biochem. 103 (2009) 1579–1584.
[22] C. Exley, N.C. Price, S.M. Kelly, J.D. Birchall, An interaction of -amyloid with
aluminium in vitro, FEBS Lett. 324 (1993) 293–295.
[23] C. Exley, The coordination chemistry of aluminium in neurodegenerative
disease, Coord. Chem. Rev. 256 (2012) 2142–2146.
